Market news

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences: Citi's 2026 Biopharma Back to School ConferenceLocation: New York, NYInvestor Meetings: Wednesday, September 9 2026 Cantor Global Healthcare ConferenceLocati

Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts. See our latest analysis for Ardelyx. The guidance cut and lowered expectations for IBSRELA have come alongside a sharp reset in Ardelyx’s share price, with the stock down 23.43% on a 30 day share price return basis and 36.33% on a 1 year total shareholder return...

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.

In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.

Ardelyx Inc (ARDX) delivers 31% revenue growth in Q2 2026 while navigating payer-imposed challenges that led to a lowered Ibsrela outlook and withdrawal of Xphozah guidance.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents and investments as of June 30, 2026 Revising FY 2026 and long-term guidance Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARD

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business

Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patients. Claude is bullish on the stock because the price has not caught up to the company’s […]

Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.